Sun Pharma Shines Again With Re-launched Starhaler; Aims For U.S. IND Filing Next Year
This article was originally published in PharmAsia News
Slowly but surely the Indian company is advancing its innovative drug pipeline.
You may also be interested in...
The "first to market" generic salmeterol inhaler, which Teva is pricing at a 15% discount to Serevent, might help to pave the way for a much more lucrative opportunity - generic Advair.
Merck Emerging Markets President Kevin Ali On The Branded Generics Business: An Interview With PharmAsia News (Part 1 of 2)
When Merck & Co. Inc. Emerging Markets President Kevin Ali speaks of innovation, it is emblematic of Merck's deep-rooted focus on new drug discovery, but the veteran executive now sees opportunities in the differentiated, branded generics segment. On a recent visit to India, Ali spoke to PharmAsia News' India Bureau about incrementally innovative drugs, access to affordable medicines and also Merck's plans in the BRIC-MT nations.
Merck Establishes JV With India's Sun Pharma To Develop Novel Combinations Of Branded Generics For Emerging Markets
MUMBAI - Merck & Co. is establishing a joint venture with India's Sun Pharmaceutical Industries Ltd. for a broad-based alliance to develop, manufacture and commercialize novel combinations and "incrementally innovative" branded generics in emerging markets, the two companies announced April 11